Katya Losk1,2, Rachel A Freedman3,4,5, Alison Laws6, Olga Kantor6, Elizabeth A Mittendorf4,5,6, Zhenying Tan-Wasielewski7, Lorenzo Trippa7, Nancy U Lin3,4,5, Eric P Winer3,4,5, Tari A King4,5,6. 1. Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, 02215, USA. katya_losk@dfci.harvard.edu. 2. Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA, USA. katya_losk@dfci.harvard.edu. 3. Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, 02215, USA. 4. Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA, USA. 5. Harvard Medical School, Boston, MA, USA. 6. Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA. 7. Department of Biostatistics, Dana-Farber Cancer Institute, Boston, MA, USA.
Abstract
PURPOSE: In 2016, we initiated standardized "reflex" Oncotype DX Recurrence Score (RS) testing for patients ≤ 65 years with pT1-2N0-1 HR+/HER2- breast cancer. Here, we examine RS testing patterns, RS distribution, and factors associated with chemotherapy use in patients with pN1 breast cancer. METHODS: Patients with stage I-III HR+/HER2- pN1 breast cancer treated with upfront surgery from February 2016 to March 2019 were identified. Clinical characteristics were compared between patients meeting reflex RS testing criteria, those with RS ordered outside of reflex criteria, and those without RS testing. RS was categorized as low (< 18), intermediate (18-30), and high (≥ 31). Multivariate logistic regression was performed to identify factors associated with adjuvant chemotherapy receipt. We examined 3-year recurrence-free survival (RFS) and overall survival (OS) stratified by chemotherapy use. RESULTS: We identified 347 HR+/HER2- pN1 patients; 272 (78.4%) received RS testing, and 194 (71.3%) met reflex criteria. RS was < 18 in 164 (61.4%) patients, 18-30 in 89 (32.7%) patients, and ≥ 31 in 16 (5.9%) patients. On multivariate analysis, RS < 18 (OR 0.47, 95% CI 0.24-0.92) was associated with lower odds of chemotherapy use, whereas presence of lymphovascular invasion (OR 1.77, 95% CI 1.03-3.07) and lobular subtype (OR 2.40, 95% CI 1.21-4.78) were associated with higher odds. No differences in 3-year RFS (p = 0.97) or OS (p = 0.19) based on chemotherapy receipt were observed. CONCLUSION: Most RS-tested HR+/HER2- pN1 patients at our center had low genomic risk. A low RS independently influenced chemotherapy omission and in RS-tested patients, short-term outcomes were excellent. Our study demonstrates increased use of RS in guiding adjuvant treatment decisions in node-positive disease.
PURPOSE: In 2016, we initiated standardized "reflex" Oncotype DX Recurrence Score (RS) testing for patients ≤ 65 years with pT1-2N0-1 HR+/HER2- breast cancer. Here, we examine RS testing patterns, RS distribution, and factors associated with chemotherapy use in patients with pN1breast cancer. METHODS:Patients with stage I-III HR+/HER2- pN1breast cancer treated with upfront surgery from February 2016 to March 2019 were identified. Clinical characteristics were compared between patients meeting reflex RS testing criteria, those with RS ordered outside of reflex criteria, and those without RS testing. RS was categorized as low (< 18), intermediate (18-30), and high (≥ 31). Multivariate logistic regression was performed to identify factors associated with adjuvant chemotherapy receipt. We examined 3-year recurrence-free survival (RFS) and overall survival (OS) stratified by chemotherapy use. RESULTS: We identified 347 HR+/HER2- pN1patients; 272 (78.4%) received RS testing, and 194 (71.3%) met reflex criteria. RS was < 18 in 164 (61.4%) patients, 18-30 in 89 (32.7%) patients, and ≥ 31 in 16 (5.9%) patients. On multivariate analysis, RS < 18 (OR 0.47, 95% CI 0.24-0.92) was associated with lower odds of chemotherapy use, whereas presence of lymphovascular invasion (OR 1.77, 95% CI 1.03-3.07) and lobular subtype (OR 2.40, 95% CI 1.21-4.78) were associated with higher odds. No differences in 3-year RFS (p = 0.97) or OS (p = 0.19) based on chemotherapy receipt were observed. CONCLUSION: Most RS-tested HR+/HER2- pN1patients at our center had low genomic risk. A low RS independently influenced chemotherapy omission and in RS-tested patients, short-term outcomes were excellent. Our study demonstrates increased use of RS in guiding adjuvant treatment decisions in node-positive disease.
Authors: Soonmyung Paik; Gong Tang; Steven Shak; Chungyeul Kim; Joffre Baker; Wanseop Kim; Maureen Cronin; Frederick L Baehner; Drew Watson; John Bryant; Joseph P Costantino; Charles E Geyer; D Lawrence Wickerham; Norman Wolmark Journal: J Clin Oncol Date: 2006-05-23 Impact factor: 44.544
Authors: Soonmyung Paik; Steven Shak; Gong Tang; Chungyeul Kim; Joffre Baker; Maureen Cronin; Frederick L Baehner; Michael G Walker; Drew Watson; Taesung Park; William Hiller; Edwin R Fisher; D Lawrence Wickerham; John Bryant; Norman Wolmark Journal: N Engl J Med Date: 2004-12-10 Impact factor: 91.245
Authors: Eleftherios P Mamounas; Gong Tang; Soonmyung Paik; Frederick L Baehner; Qing Liu; Jong-Hyeon Jeong; S Rim Kim; Steven M Butler; Farid Jamshidian; Diana B Cherbavaz; Amy P Sing; Steven Shak; Thomas B Julian; Barry C Lembersky; D Lawrence Wickerham; Joseph P Costantino; Norman Wolmark Journal: Breast Cancer Res Treat Date: 2017-11-11 Impact factor: 4.872
Authors: Kathy S Albain; William E Barlow; Steven Shak; Gabriel N Hortobagyi; Robert B Livingston; I-Tien Yeh; Peter Ravdin; Roberto Bugarini; Frederick L Baehner; Nancy E Davidson; George W Sledge; Eric P Winer; Clifford Hudis; James N Ingle; Edith A Perez; Kathleen I Pritchard; Lois Shepherd; Julie R Gralow; Carl Yoshizawa; D Craig Allred; C Kent Osborne; Daniel F Hayes Journal: Lancet Oncol Date: 2009-12-10 Impact factor: 41.316
Authors: Lyndsay Harris; Herbert Fritsche; Robert Mennel; Larry Norton; Peter Ravdin; Sheila Taube; Mark R Somerfield; Daniel F Hayes; Robert C Bast Journal: J Clin Oncol Date: 2007-10-22 Impact factor: 44.544
Authors: Joseph A Sparano; Robert J Gray; Della F Makower; Kathleen I Pritchard; Kathy S Albain; Daniel F Hayes; Charles E Geyer; Elizabeth C Dees; Matthew P Goetz; John A Olson; Tracy Lively; Sunil S Badve; Thomas J Saphner; Lynne I Wagner; Timothy J Whelan; Matthew J Ellis; Soonmyung Paik; William C Wood; Peter M Ravdin; Maccon M Keane; Henry L Gomez Moreno; Pavan S Reddy; Timothy F Goggins; Ingrid A Mayer; Adam M Brufsky; Deborah L Toppmeyer; Virginia G Kaklamani; Jeffrey L Berenberg; Jeffrey Abrams; George W Sledge Journal: N Engl J Med Date: 2018-06-03 Impact factor: 91.245
Authors: Mitch Dowsett; Jack Cuzick; Christopher Wale; John Forbes; Elizabeth A Mallon; Janine Salter; Emma Quinn; Anita Dunbier; Michael Baum; Aman Buzdar; Anthony Howell; Roberto Bugarini; Frederick L Baehner; Steven Shak Journal: J Clin Oncol Date: 2010-03-08 Impact factor: 44.544
Authors: Salomon M Stemmer; Shmuel H Klang; Noa Ben-Baruch; David B Geffen; Mariana Steiner; Lior Soussan-Gutman; Shahar Merling; Christer Svedman; Shulamith Rizel; Nicky Lieberman Journal: Breast Cancer Res Treat Date: 2013-06-26 Impact factor: 4.872
Authors: Frédérique Penault-Llorca; Thomas Filleron; Bernard Asselain; Frederick L Baehner; Pierre Fumoleau; Magali Lacroix-Triki; Joseph M Anderson; Carl Yoshizawa; Diana B Cherbavaz; Steven Shak; Lise Roca; Christine Sagan; Jérôme Lemonnier; Anne-Laure Martin; Henri Roché Journal: BMC Cancer Date: 2018-05-04 Impact factor: 4.430
Authors: Kathleen Iles; Mya L Roberson; Philip Spanheimer; Kristalyn Gallagher; David W Ollila; Paula D Strassle; Stephanie Downs-Canner Journal: NPJ Breast Cancer Date: 2022-03-01